Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001211151 | SCV001382676 | uncertain significance | Epileptic encephalopathy | 2024-06-05 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 1433 of the RYR3 protein (p.Thr1433Ala). This variant is present in population databases (rs201020040, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with RYR3-related conditions. ClinVar contains an entry for this variant (Variation ID: 941374). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RYR3 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004659393 | SCV005158878 | uncertain significance | not specified | 2024-04-06 | criteria provided, single submitter | clinical testing | The c.4297A>G (p.T1433A) alteration is located in exon 32 (coding exon 32) of the RYR3 gene. This alteration results from a A to G substitution at nucleotide position 4297, causing the threonine (T) at amino acid position 1433 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |